A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

This study tests a type of immune cell therapy called CAR-T cells that are engineered to target a protein called CEA, which is found on the surface of several types of advanced solid tumors. The goal is to see if this therapy is safe and effective for patients whose cancer has progressed. **You may be eligible if...** - You are 18 or older - You have advanced colorectal, esophageal, gastric, pancreatic, non-small cell lung, breast, or bile duct cancer confirmed by biopsy or pathology - Your tumor tests positive for the CEA protein - Prior standard treatments have not worked **You may NOT be eligible if...** - You have uncontrolled active infections or serious organ problems - You have brain metastases that are unstable or untreated - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.